PharosBio provides an AI‑powered decision‑support platform that unifies experimental data, publications, and internal documents for pharmaceutical and biotech R&D teams. The system generates hypothesis‑driven insights, predicts preclinical translatability, and matches clinical studies to observed outcomes, delivering traceable, actionable recommendations while meeting enterprise security and compliance standards.
Funding
Funding not disclosed
Founders
Product
Problem
Pharmaceutical and biotech teams struggle with fragmented experimental data, publications, and internal documents, leading to poor pipeline oversight and low drug‑development success rates. The lack of FAIR data practices and integrated analytics forces scientists to rely on manual tools, causing missed insights and inefficient decision‑making.
Solution
PharosBio offers an AI‑powered decision‑support platform that acts as an operating system for life‑science research, unifying data from early discovery through clinical stages. By ingesting experimental results, literature, and internal knowledge bases, the system generates hypothesis‑driven insights, predicts preclinical translatability, and matches clinical studies to observed outcomes. All analyses are traceable, with role‑based access, encryption at rest and in transit, and compliance with GDPR, SOC2, and HIPAA. The platform delivers actionable recommendations quickly, helping scientists prioritize targets, reduce costly trial failures, and accelerate drug development timelines.
Target Audience
Primary customers are R&D teams in pharmaceutical companies and biotech firms that need integrated, AI‑enhanced analytics across discovery, preclinical, and clinical phases.
Features
- Automated data integration across publications, experimental results, and internal documents following FAIR principles
- AI‑driven hypothesis generation and target prioritization for early discovery
- Explainable models that predict the translatability of in‑vivo findings to clinical outcomes
- Clinical study similarity engine that identifies comparable trials based on measured biomarkers
- Enterprise‑grade security: encryption at rest/in transit, role‑based access controls, audit logs, and compliance certifications (GDPR, SOC2, HIPAA)
- Traceable analytics pipeline with full auditability of data provenance and model decisions